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Abstract
Introduction: Cholangiocarcinoma is a rare malignancy of the biliary tract, the incidence of which is rising, but the
pathogenesis of which remains uncertain. No common genetic defects have been described but it is accepted that chronic
inflammation is an important contributing factor. We have shown that primary human cholangiocyte and hepatocyte
survival is tightly regulated via co-operative interactions between two tumour necrosis family (TNF) receptor family
members; CD40 and Fas (CD95). Functional deficiency of CD154, the ligand for CD40, leads to a failure of clearance of biliary
tract infections and a predisposition to cholangiocarcinoma implying a direct link between TNF receptor-mediated
apoptosis and the development of cholangiocarcinoma.
Aims: To determine whether malignant cholangiocytes display defects in CD40 mediated apoptosis. By comparing CD40
and Fas-mediated apoptosis and intracellular signalling in primary human cholangiocytes and three cholangiocyte cell lines.
Results: Primary cholangiocytes and cholangiocyte cell lines were relatively insensitive to direct Fas-mediated killing with
exogenous FasL when compared with Jurkat cells, which readily underwent Fas-mediated apoptosis, but were extremely
sensitive to CD154 stimulation. The sensitivity of cells to CD40 activation was similar in magnitude in both primary and
malignant cells and was STAT-3 and AP-1 dependent in both.
Conclusions: 1) Both primary and malignant cholangiocytes are relatively resistant to Fas–mediated killing but show
exquisite sensitivity to CD154, suggesting that the CD40 pathway is intact and fully functional in both primary and
malignant cholangiocytes 2) The relative insensitivity of cholangiocytes to Fas activation demonstrates the importance of
CD40 augmentation of Fas dependent death in these cells. Agonistic therapies which target CD40 and associated
intracellular signalling pathways may be effective in promoting apoptosis of malignant cholangiocytes.
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Introduction
Fas (CD95) is a prototypic death inducing receptor of the TNF
receptor superfamily which induces death by apoptosis when
engaged by its ligand FasL (CD178) [1,2]. Fas is widely expressed
in the heart, liver, spleen and thymus [3] and regulated expression
of CD178 is critical to prevent uncontrolled Fas activation in B
lymphocytes [4]. The liver expresses low levels of Fas constitutively
which increase rapidly during inflammation rendering hepatocytes
potentially susceptible to Fas-mediated death. Biliary cells in
primary biliary cirrhosis (PBC) were originally reported to undergo
apoptosis in response to FasL cross linking which contributes to
progressive bile duct loss [5]. In addition to Fas, liver epithelial
cells express other death receptors of the TNF Receptor
superfamily (TNFR) in response to inflammation or infection
including TRAIL receptors, TNFR1/2, and CD40 rendering
them susceptible to apoptosis via several receptors [6].
CD40, a 50 kDa cell surface type I glycoprotein first discovered
on B cells, lacks a classical death domain [7]. The cognate ligand
for CD40, CD154 (CD40 ligand, CD40L, gp39, TRAP) does not
bind other TNFR although it can interact with the soluble
complement inhibitor C4b binding protein which may function as
a competitive inhibitor of CD40 activation [8]. CD154 is a type II
transmembrane protein that retains activity as a soluble trimer. It
is expressed on the surface of several cell types including activated
T lymphocytes and macrophages [9,10].
CD40 on B cells regulates cell survival, proliferation and isotype
class switching [11]. Patients with X-linked hyper IgM syndrome
have a mutation in the CD154 gene, which is associated with
enhanced susceptibility to Pneumocystis Carinii, Cryptosporidosis and
development of biliary tract, liver and pancreatic tumours [12].
The presence of CD40 on the majority of carcinomas [13], its
absence or low constitutive expression on normal tissue, and
inducibility of CD40 by pro-inflammatory cytokines such as TNFa
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and IFN-c indicate a potential role for CD40 in the development
of malignancy at sites where there is chronic inflammation [14].
That there are approximately 27 TNFR compared with 19
known TNF ligands implies shared receptors and integrated
signaling pathways; for example all members of the TNF
superfamily can activate NF-kB albeit to varying degrees [15].
We were the first group to demonstrate that CD40 activation
induces Fas-dependent apoptosis of hepatocytes via induction of
autocrine/paracrine FasL in vitro, and may amplify hepatocyte loss
in liver injury [16]. Our subsequent work demonstrated that CD40
and Fas are expressed by cholangiocytes (biliary epithelial cells) in
inflamed portal tracts and ligation of cholangiocyte CD40 by
CD154 leads to autocrine or paracrine amplification of Fas
mediated apoptosis mediated through sustained activation of AP-1
(JNK/ERK) and JAK2 dependent activation of STAT-3 [17,18].
Cholangiocarcinoma is a rare but rapidly increasing malignancy
of the biliary tract [19]. It is usually diagnosed late and average 5
year survival rates are only 5%–10%. Cholangiocarcinoma is 10
times more common in Japan and Southeast Asia due to a high
incidence of Clonorchis sinensis and Clonorchis viverrini parasitic
infections [20]. Other risk factors for cholangiocarcinoma include
hepatolithiasis [21], abnormal biliary anatomy (15% increased
risk) [22], chronic hepatitis B or C infection [23] and primary
sclerosing cholangitis, a chronic inflammatory and scarring disease
of the bile ducts [24]. The pathogenesis of cholangiocarcinoma
development in biliary disease is unknown but chronic inflamma-
tion, bile salt toxicity and chronic bacterial contamination have all
been implicated [25].
Constitutive activation of the CD40 pathway has been implicated
in cell transformation and neoplastic growth [26]. Paradoxically
some ovarian and cervical cancer cell lines express CD40 and can
be induced to undergo apoptosis when stimulated with a range of
TNF ligands [27]. This prompted us to investigate whether CD40 is
expressed in cholangiocarcinoma and if so whether it is functional
and therefore a potential therapeutic target.
We report that cholangiocarcinoma cells express functional
CD40 and undergo apoptosis when stimulated with soluble
trimeric CD154. This was associated with an increase in FasL
mRNA and signaling via AP-1 (c-Fos/c-Jun) and STAT-3. We
also show for the first time that both cholangiocarcinoma cell lines
and primary cholangiocytes were comparatively insensitive to
directly stimulation with exogenous FasL despite expressing
abundant levels of cell surface Fas. These observations shed
further light on TNFR mediated mechanisms which control
epithelial cell fate and have important implications for therapeutic
approaches to treatment of cholangiocarcinoma.
Materials and Methods
2.1. Sources of liver tissue and isolation of cholangiocytes
Cholangiocytes were isolated from a variety of end stage liver
disease tissue removed at transplantation and from non-diseased
liver tissue from organs that were surplus to transplant
requirements [28]. All tissue was obtained from fully informed
patients with written consent. Ethical approval for the study was
granted by the South Birmingham Research Ethics Committee
(LREC ref. CA/5192). Liver tissue underwent mechanical and
enzymatic digestion with Collagenase type 1A (Sigma Aldrich,
Dorset, UK) and density gradient centrifugation on 33%/77%
Percoll. Cholangiocytes were further purified by immunomagnetic
isolation using antibodies against the cholangiocyte-specific
receptor HEA 125 (Progen, Heidelberg, Germany). The cells
were cultured in Dulbecco’s Modified Eagle medium, Hams F12
plus 10% heat-inactivated human serum, glutamine (2 mM),
hepatocyte growth factor (10 ng/ml, Peprotech, London, UK),
epidermal growth factor (10 ng/ml, Peprotech), hydrocortisone
(2 mg/ml), cholera toxin (10 ng/ml, Sigma Aldrich), tri-iodo-
thyronine (2 nM, Sigma Aldrich) and insulin (0.124 U/ml) with
penicillin (100 IU/ml) and streptomycin (100 mg/ml, Gibco,
California, USA). Cells were cultured to confluence in tissue
culture flasks coated with rat tail collagen.
Cells were harvested by gentle trypsinization (Invitrogen) and
used between passage 2 and 5 to ensure phenotypic stability.
AKN-1 (a gift from Dr A Nussler, University of Ulm, Germany),
CC-LP-1 and CC-SW-1 (a gift from Dr P Bosma, AMC Liver
Centre, University of Amsterdam, Netherlands) were maintained in
DMEMwith 10% FCS, L-glutamine (2 mM), penicillin (100 U/ml)
and streptomycin (100 mg/ml) on uncoated flasks. Jurkat cells were
maintained in RPMI 1640 (Invitrogen) with 10% FCS, L-glutamine
(2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml).
2.2 Expression of CD40, Fas and FasL by flow cytometry
Cell surface expression of CD40, Fas or FasL was assessed by
flow cytometry using a Coulter Epics XL flow cytometer and the
following antibodies: CD40-PE (10 mg/ml, Axxora, Bingham,
UK), Fas-PE (10 mg/ml, Dako, Ely, UK) and FasL-PE (4 mg/ml,
BD Pharmingen, Oxford, UK) with an isotype-matched IgG1-PE
antibody (10 mg/ml, Dako). All data were analysed using
Cytomation Summit v3.1 (Dako).
2.3 Assessment of FasL involvement in apoptosis by RT-
PCR
Cholangiocyte FasL mRNA expression was measured by RT-
PCR after incubation of cells with soluble recombinant human
(srh) trimeric CD154 (1 mg/ml, Axxora, ALX-522-015), or soluble
recombinant human FasL (50 ng/ml, Axxora, ALX-522-001) for
24 hours. The concentrations of CD154 and FasL were optimum
as used in previously published studies [16,17,18]. The ligand
concentrations were determined by titration against primary
hepatocytes or cholangiocytes (for CD154) or against a Fashigh
Jurkat cell line. No further increases in apoptosis was observed
with higher concentrations of either ligand on the primary cells
(data not shown) or on the Jurkat cell line where 50 ng/ml result in
apoptosis of .90% of the total population. Total RNA was
extracted with the Qiagen RNEasy kit (Qiagen, Crawley, UK)
according to the manufacturer’s protocol. FasL and b-actin
mRNA were detected using RT-PCR. Primer pairs for FasL
and b-actin were synthesized by Alta Bioscience Ltd. (Birming-
ham, UK) using the following sequences: FasL forward 59-
ACTGGCAGCATCTTCACTTC-39 and reverse 59-TTCAAA-
ATCTTGACCAAATGC-39, b-actin forward 59-CATCAC-
CATTGGCAATGAGC-39 and reverse 59-ATCCACACGGAG-
TACTTG-39. Reverse transcription (RT) was carried out using a
standard protocol incubating the RT mix at room temperature for
10 min, followed by 1 h at 42uC and 5 min at 95uC. Samples were
held at 4uC before PCR amplification according to the following
cycling program: 2 min denaturation at 96uC, followed by 35
cycles of 30 seconds at 96uC, 1 minute at 55uC, and 1 minute at
72uC with a final extension for 10 minutes at 72uC. Samples were
held at 4uC overnight. After PCR amplification, samples were
electrophoresed in 2% agarose gel and stained with ethidium
bromide.
2.4 Transcription factor activation in cells following
stimulation with CD154
Cholangiocyte monolayers were treated with srh CD154 (1 mg/
ml), srh FasL (50 ng/ml) or srh TNFa (10 ng/ml Peprotech) for
CD40 and Fas Mediated Death
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24 hours. Monolayers were then harvested by scraping into ice
cold PBS. Cytoplasmic and nuclear protein extracts were
prepared using a standard protocol [29] and protein content of
each sample determined using the Micro Lowry Total Protein Kit
(Sigma, according to the manufacturer’s instructions). Samples
(40 mg protein) were resolved on a 10% Bis-Acrylamide gel by
SDS-PAGE, followed by transfer to nitrocellulose membrane
(Amersham Pharmacia Biotech, Buckinghamshire, UK). Mem-
branes were blocked overnight at 4uC in phosphate-buffered
saline (PBS) containing 5% w/v non-fat dried milk and then
washed (3610 minutes) with 0.1% Tween-20/PBS, before
incubating with primary antibodies. All incubations were for
1 hour at room temperature in PBS Tween containing 5% w/v
non-fat dried milk. The following antibodies were used; a)
phospho-STAT3 mouse monoclonal antibody at 0.2 mg/ml
(Santa Cruz Biotechnology Inc. Cat. No. sc-8059, Santa Cruz,
CA, USA). b) c-Fos rabbit polyclonal primary antibody at
0.4 mg/ml (Santa Cruz Biotechnology Inc. Cat. No. sc-52). c) c-
Jun rabbit polyclonal primary antibody at 0.4 mg/ml (Santa Cruz
Biotechnology Inc. Cat. No. sc-44) and d) b-actin mouse
monoclonal antibody at 0.4 mg/ml (Sigma, Cat. No. A5441).
Antibodies were detected using either horse radish peroxidase
(HRP) conjugated rabbit anti mouse IgG (1.3 mg/ml) for 1 hour
at room temperature or HRP conjugated goat anti rabbit IgG
(0.25 mg/ml) for 1 hour at room temperature (Dako). Protein
bands were visualised using enhanced chemiluminescence (Pierce
Perbio, Cramlington, UK) and exposure to Hyperfilm-ECL
(Amersham Pharmacia Biotech) and quantified by densitometry
scanning (BioRad 2000 Gel Doc system, BioRad, Hemel
Hempsted, UK). Equality of protein loading and transfer onto
membranes was confirmed by probing for b-actin and staining
with Ponceau S solution (Sigma).
2.5 Assessment of apoptosis by in situ DNA end labelling
(ISEL) staining
Apoptosis was quantified by ISEL staining and assessment of
morphology on cytospin preparations of cholangiocytes as
previously described [30,31].
Cholangiocytes were incubated for 24 hours in a) medium alone
b) 1 mg/ml srh CD154, a concentration previously shown to
provide optimal induction of apoptosis in these cells [15] or srh
FasL 50 ng/ml (optimal dose for induction of apoptosis in the
Jurkat cell line).
2.6 Statistical analysis
Data are expressed as the mean 6 SD from at least three
experiments unless otherwise stated. A Student’s unpaired t-test
was used to compare individual data with control values. A
probability of P,0.05 was taken as denoting a significant
difference from control data. All primary cell culture experiments
were carried out a minimum of 3 times.
Results
Protein expression of CD40, Fas and FasL on isolated
cholangiocytes
In the absence of stimulation cultured primary human
cholangiocytes and the cell lines expressed CD40, high levels of
Fas and very low levels of FasL. Fas and FasL levels were
unchanged by the addition of IFN-c to the culture media for
48 hours whereas CD40 expression increased significantly in
response to IFN-c in all cell types except AKN-1 cells (figure 1).
Induction of FasL mRNA following CD40 activation on
cholangiocarcinoma cell lines and primary
cholangiocytes
Activation of cholangiocarcinoma cell lines or primary cholan-
giocytes with soluble trimeric CD154 resulted in a significant
increase in FasL mRNA after 4 hours stimulation compared with
basal levels in unstimulated cells. Although the results for the CC-
LP-1 cell line failed to reach statistical significance (when
compared to b-actin controls) the trend was the same as the
other two cell lines and the primary cells (figure 2).
Transcription factor activation in cholangiocarcinoma
cells compared with primary cholangiocytes
We previously reported [17] that activation of cholangiocytes by
CD40 ligation results in sustained upregulation of c-Fos/c-Jun
(AP-1 subunits) and phosphorylation of STAT3 and apoptotic cell
death [18]. Here although there was some variation in the
magnitude of response between cells types, the trend/activation
profile was similar to the primary cells in all three cholangiocarci-
noma cell lines (figure 3). pSTAT-3, c-Fos and c-Jun increased in
all cells following stimulation with CD154 compared to unstimu-
lated cells or those stimulated with FasL or TNFa.
Induction of apoptosis after stimulation with soluble
CD154 or FasL
Activation of cell-surface CD40 with srh CD154 induced similar
high levels of apoptosis in primary and malignant cells after
24 hours; whereas only the CC-SW-1 cholangiocarcinoma cell
line underwent apoptosis when stimulated with FasL for 24 hours
despite all cell lines and primary cells expressing high levels of cell
surface Fas. The Jurkat cell line was used as a positive control to
show that the srh FasL was functional and could induce apoptosis
in an appropriately sensitive cell line cultured in similar conditions
(figure 4).
Discussion
We have demonstrated that cholangiocarcinoma cells express
CD40 and like primary cholangiocytes are exquisitely sensitive
to CD154 mediated apoptosis. After stimulation with CD154
there was a sustained upregulation of FasL and induction of
apoptosis was accompanied by activation of the AP-1 (c-Fos/
c-Jun) and pSTAT-3 signalling pathways as previously reported
in primary cholangiocytes [16,17,18]. Thus the functional
elements of the CD40 death-inducing mechanism are intact in
cholangiocarcinoma.
The expression of CD40 on cholangiocarcinoma and the
increased levels of expression detected after IFN-c stimulation are
consistent with previous studies reporting CD40 expression on
other carcinomas e.g. nasopharyngeal carcinoma [32,33]. The
increased levels of CD40 seen in diseased tissue and cholangio-
carcinoma could be explained by high local levels of proin-
flammatory cytokines such as TNFa and IFN-c at sites of
persistent chronic inflammation [14].
Fas is expressed by non-malignant bile ducts and expression
increases in chronic inflammatory biliary disease and on bile
ducts that have become dysplastic [34]. Fas is also expressed in
well-differentiated cholangiocarcinoma but expression is dimin-
ished or absent from poorly differentiated tumours [34].
Cholangiocarcinoma cell lines display variable levels of Fas,
for example the extrahepatic cholangiocarcinoma cell line Sk-
ChA-1 includes a mixed population of high and low Fas-
expressing cells as determined by mRNA and protein analysis
CD40 and Fas Mediated Death
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[35,36]. Thus although cholangiocytes constitutively express Fas
and this is preserved during neoplastic transformation it can be
downregulated as the tumour becomes more genetically
unstable [34].
FasL mRNA expression has also been reported to be increased
in malignant cholangiocytes compared with the low levels detected
in non-malignant cells [37]. All three cell lines we studies showed
low expression of FasL but this was readily increased by CD154
Figure 1. Expression of CD40, Fas and FasL protein on the cell surface assessed by flow cytometry. Cells were grown in media alone or
stimulated with IFN-c at 50 ng/ml for 48 hours. (a) flow cytometry histograms of matched isotype control (red outline) and CD40, Fas and FasL
expression (green solid colour) (b) shows the percentage positive cells for CD40, Fas and FasL protein. n = 3+/2 standard deviation. *p,0.05,
**p,0.01 as compared to untreated controls.
doi:10.1371/journal.pone.0014037.g001
CD40 and Fas Mediated Death
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stimulation. Inhibition of gene transcription, alteration of
posttranscriptional modification and protein processing may
account for the low constitutive FasL expression observed.
After 4 hours incubation in media alone or with srh FasL, low
levels of FasL mRNA were detected. When cells were incubated
with soluble recombinant CD154, expression of FasL mRNA was
markedly upregulated. These data are consistent with previous
studies in which CD154 stimulation of primary non-malignant
cholangiocytes increased FasL mRNA threefold compared to
media alone. Previous studies with hepatocytes also showed that
apoptosis after stimulation with CD154 could be significantly
reduced with a blocking antibody to FasL. The sustained
upregulation of FasL may explain why the pro-apoptotic effects
of CD154 are so potent providing an essential amplification signal
to maintain FasL production and thus promote autocrine/
paracrine Fas activation [17].
Specific transcription factors have been implicated in regulating
cholangiocyte death and survival [17,18] and here we found these
were conserved in the cholangiocarcinoma cells. The signalling
pathways examined previously were characterized extensively
using specific pharmacological inhibitors and shown to be critical
for induction of cholangiocyte apoptosis after CD154 ligation.
STAT-3 was examined because it can regulate cell survival and
drive apoptosis in mammary epithelial cells [38]. Previous studies
in the liver suggested that STAT-3 is a global cell survival factor
involved in tissue regeneration but these experiments used whole
liver extracts and therefore do not show what happens to
individual cell types [39]. It is the phosphorylated form of the
molecule that conveys signals and at 24 hours after treatment with
CD154 levels of phospho STAT-3 were increased compared with
FasL stimulated or unstimulated cells suggesting that in these
circumstances and cells STAT-3 is pro-apoptotic [18]. CD40
ligation can also cause the activation of the transcription factor
complex AP-1, which consists of two heterodimer subunits c-Fos
and c-Jun [40] and these have been found to be pro-apoptotic
[41,42,43] because they form dimers capable of binding to
promoter regions of genes involved in apoptosis such as caspase 3.
Consistent with this we found increased levels of c-Fos and c-Jun in
cells undergoing apoptosis at 24 hours in response to CD154 but
not FasL. The activation demonstrated here of STAT-3 and AP-1
(c-Jun and c-Fos) following CD154 treatment suggests that these
are common pathways downstream for CD40 in both the primary
and malignant cells and are associated with apoptotic cell death. In
vivo the scenario is likely to be more complex. It may be for
example that cholangiocarcinoma cells do become increasingly
insensitive to Fas ligation and protected from CD40 induced
apoptosis as a consequence of the high levels of the CD154
antagonist C4BP found in close proximity to the tumours [8]. At
present this remains an area under active investigation in our
laboratory.
Primary cholangiocytes and cholangiocarcinoma cells intriguing
seemed to express low levels of CD40 but high levels of Fas.
However in contrast to CD154, very little apoptosis was observed
when stimulated directly with FasL. This finding was not expected
and suggests that Fas activation does not deliver a potent pro-
apoptotic signal in cholangiocytes or their malignant counterparts.
Figure 2. Fas ligand induction to promote apoptosis assessed by RT-PCR at 4 hours. Cells were grown in culture media alone, stimulated
with srh CD154 at 1 mg/ml or srh FasL at 50 ng/ml for 4 hours. (a) densitometry scanning data for FasL PCR gels at 4 hours. n = 4+/2 standard error of
the mean. (b i) a representative FasL PCR gel and (b ii) the corresponding b-actin gel. *p,0.05, **p,0.01 as compared to untreated controls.
doi:10.1371/journal.pone.0014037.g002
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Fas resistance is well-reported in several cancers [44,45] and may
provide an important survival advantage to the tumour. However
here we have demonstrated for the first time that normal
cholangiocytes are similarly insensitive to FasL. The reasons for
this are presently unknown but the fact that we can induce Fas-
dependent apoptosis via CD40 ligation in these cells suggests that
CD40 not only induces FasL expression to provide autocrine Fas
activation but that it also directly induces signals that activate the
otherwise suppressed Fas death pathway. The finding that the
lymphocyte-derived Jurkat cell line readily underwent apoptosis
when stimulated with srh FasL indicates that the differences were
due to cell type and not the biological activity of the ligand.
When any of the cell types were challenged with soluble CD154,
the majority underwent apoptosis, with the cell lines being equally
as sensitive as the primary cells. The response of primary
cholangiocytes is consistent with what we have shown previously
[17] but differ from a study which reported that both non-
malignant and malignant urothelial cells failed to undergo
apoptosis when stimulated with soluble CD154, whereas cell-
bound CD154 induced apoptosis of the malignant cell lines. This
Figure 3. Transcription factor activation in cells undergoing apoptosis after stimulation with soluble TNF ligands. Cells were grown in
media alone, with srh CD154 at 1 mg/ml, srh FasL at 50 ng/ml or srh TNFa at 10 ng/ml for 24 hours. Graphs show densitometry scanning data, n = 3+/
2 standard deviation and representative autoradiographs of primary cholangiocyte samples showing (a) pSTAT-3 (60 kDa), (b) c-Fos (60 kDa) and (c)
c-Jun (35 kDa) all with their corresponding b-actin blots (45 kDa). *p,0.05, **p,0.01, ***p,0.001 as compared to untreated controls.
doi:10.1371/journal.pone.0014037.g003
CD40 and Fas Mediated Death
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Figure 4. Apoptosis induction in cholangiocytes after stimulation with soluble TNF ligands. All cells were cytocentrifuged and stained by
the standard ISEL technique to detect apoptosis after culture in media alone, media with srh CD154 at 1 mg/ml or media with srh FasL at 50 ng/ml for
24 hours. All control slides without DNA polymerase klenow fragment were negative (a i). (a ii) primary cholangiocytes in media alone, (a iii) shows
primary cholangiocytes stimulated with soluble CD154 and (a iv) primary cholangiocytes challenged with soluble FasL. (b) shows the percentage
positive ISEL stained cells in all cell types when grown in media alone, with CD154 or with FasL. n = 3+/2 standard deviation. *p,0.05, **p0.01,
***p,0.001 as compared to untreated controls.
doi:10.1371/journal.pone.0014037.g004
CD40 and Fas Mediated Death
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lead the authors to conclude that mode of ligand presentation was
important for the induction of apoptosis [46]. That we saw
responses with srh CD154 might relate to the nature of the ligand
we used but suggests also that ligand presentation may not be
critical for this pathway.
At least one previous study reported that a CD40 positive
tumour cell line resistant to Fas cytotoxicity was susceptible to
TNFR or CD40-mediated death [47]. It has been known for a
number of years that members of the TNF superfamily can
interact with each other, and this includes CD40 and Fas. While
some studies showed that stimulating the CD40 receptor inhibits
Fas-induced apoptosis in normal and neoplastic cells [48,49],
many more have shown that CD40 and Fas can synergize to
enhance the apoptosis signal to increase cell death and that
receptor levels on the cell surface may determine the outcome.
Other studies have examined the CD40/Fas costimulatory effects
on apoptosis in malignant cells and found that this also occurs in a
range of tumour cell lines including the human myeloma cell line
XG2 [50], B cell lymphoma cells [51], breast carcinoma cell lines
[52] and chronic lymphocytic leukemia cells [53]. Chu and
colleagues reported that CD40 ligation on CLL B cells induced a
programme of events in which shifts in the balance of anti-
apoptotic and pro-apoptotic FLIP and FADD were associated with
initial resistance to Fas-mediated killing followed by subsequent
sensitization. A similar mechanism could be operating in these
cholangiocarcinoma cells that are resistant to direct Fas ligation
but die in a Fas-dependent process after CD40 ligation. Here we
have shown that similar mechanisms apply to cholangiocarcinoma
cells.
One of the most interesting findings in this study was that
despite the apparent low levels of CD40 on the cell surface, all of
the cholangiocarcinoma cell lines nevertheless under went high
levels of apoptosis. This apparent lack of correlation between
receptor levels and biological effect may be explained by
differences in receptor density and/or occupancy. The importance
of receptor occupancy and CD154 concentration in determining
functional outcome has been reported previously in Burkitt
lymphoma cells where high concentrations of CD154 suppressed
proliferation while low concentrations of CD154 sustained growth
[54]. Another and possibly more likely explanation was that only a
small subpopulation of cells are required to express CD40 which
once stimulated express and present sufficient FasL to drive
apoptosis in Fas expressing neighboring cells in a juxtacrine or
paracrine manner. This clearly warrants further studies which are
beyond the scope of the present investigation but if correct it
suggests that under these circumstances it is the juxtacrine/
paracrine mechanism of FasL presentation which predominates as
a mechanism for regulation of apoptosis in cholangiocytes. This
remains speculative but worthy of future investigation.
Because CD40 is upregulated in many cancers it is a potential
target for anti-cancer therapy. Recombinant CD154 has been
used in a phase I clinical trial in patients with either advanced solid
tumours or high grade non-Hodgkin’s lymphoma with some
evidence of efficacy and little evidence of serious toxicity [55]. A
humanized anti-CD154 antibody (hu5C8) was developed with the
objective of suppressing CD40-mediated immune activation in
autoimmune disease and transplantation but clinical trails were
complicated by increased thromboembolic events and had to be
halted [56]. Anti-human CD154 antibody (AB1793) has subse-
quently been shown to prevent kidney allograft rejection in
monkeys presumably by suppression of immune cell activation
[57] but also possibly by inhibiting renal epithelial cell loss
resulting from similar mechanisms to those proposed in the liver.
The authors concluded that the thromboembolic events seen
previously were antibody class-specific thus reviving enthusiasm
for its clinical use.
Tumours which express CD40 can stimulate the generation of
anti-tumour effector cells [58] and CD40 activation in vivo
enhances the survival of activated T cells [59] and promotes DC
accumulation and survival [60]. CD154 has been transduced into
murine tumours in a mouse model of prostate cancer to reduce cell
viability and increase apoptosis. Vaccination of CD154-expressing
cells induced anti-tumour immunity and peritumoural injections
induced tumour growth suppression [61]. There is growing
evidence that macrophages are capable of killing tumour cells
[62] and our previous studies reporting that CD154-bearing
macrophages are present in the human liver and can induce
apoptosis in CD40-expressing cholangiocytes [63] suggests
another mechanism through which CD40 could mediated anti-
tumour responses in cholangiocarcinoma.
In this study we have shown that cholangiocarcinoma cells lines
are resistant to Fas–mediated killing but show sensitivity to CD40
mediated apoptosis suggesting that CD154 therapy might be
effective in the treatment and management of cholangiocarci-
noma. CD40/CD154 therapy in cholangiocarcinoma could work
in two ways; by stimulating anti-tumour responses in leukocytes,
and by the indirect promotion of cell death via CD40-dependent
induction of FasL. However caution is necessary because there is
the potential for inducing death of non-malignant cholangiocytes if
the treatment is not targeted to the tumour.
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